Neurocrine Biosciences (NBIX) Tops Q3 EPS by 58c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $142.70 -0.41%
EPS Growth %: -12.0%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -12.0%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $2.17, $0.58 better than the analyst estimate of $1.59. Revenue for the quarter came in at $794.9 million versus the consensus estimate of $748.62 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Zefiro Methane closes C$5M non-brokered private placement
- Therma Bright plans $420,000 non-brokered private placement
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
